ГЛАBА 2. СОМАТИЧЕСКАЯ ПАТОЛОГИЯ И ЕЕ ПАТОГЕНЕТИЧЕСКИЕ МЕХАНИЗМЫ У ЛИКВИДАТОРОВ ПОСЛЕДСТВИЙ АВАРИИ НА ЧАЭС

Holland P. et al. In vivo expression of mRNA for Cabinding protein SPARK (osteonectin) revealed by in situ hybridization / P. Holland., S. Harpes., J.McVey et al. // J.Cell. Biol. – 1987. – Vol. 105, N 1. – P. 473-478.

Hughes D.E., Wright K.R., Uy H.L. et al. isphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo // J. Bone. Miner. Res. 1995. – Vol. 10. – P. 1478-1487.

Institute for Clinical Systems Improvement (ICS) Health Care Guideline: Diagnosis and Treatment of Ostejporosis, 3rd edition, July 2004.

Institute for Clinical Systems Improvement (ICSI) Health Care Guideline for Patients and Families, July 2006.

Кhan A., Hodsman A., Papaioannou A. et al. Management of osteoporosis in men: an update and case example 2007.

Krege J.H., Siminoski K., Adachi J.D. et al. // A simple method for determining the probability a new vertebral fracture is present in postmenopausal women with osteoporosis // Osteoporos. Int. – 2006. – Vol. 17, N 3. – Р. 379-386.

Kroger H., Reeve J. Diagnosis of osteoporosis in clinical practice // Ann. Med. – 1998. – Vol. 30, N 3. – P. 278-287.

Liu H., Paige N.M., Goldzweig C.L. et al. Screening for osteoporosis in men: A systematic review for an American college of physicians guideline // Annals of internal medicine. – 2008. – Vol. 148, N 9. – P. 685-701.

Lommeaau J. SHBG and BM // Bone. – 2004. – Vol. 34. – P. 933-939.

Lowik CWGM., van der Pluijm G., Bloys H. et al. Parathyroid hormone and PTH-like protein stimulate interleukin-6 production by osteogenic cells: a possible // Res. Commun. – 1999. – N 162. – P. 1546-1552.

Lyles K.W., Colon-Emeric C.S., Magaziner J.S. et al. Zoledronic acid in reducing clinical frature and mortality after hip fracture // New Engl. J. Med. - 2007. – P. 357.

Machann J., Schick F., Seitz D. et al. Untersuchung spongioser Knochenanteile im Fussskelett mit bildgebenden MR-Verfahren // Biomed. Tech. – 1998. – Bd 43, N 7-8. – S. 202-209.

Malkin C.J., Pugh P.J., Jones R.D., Jones T.H., Channer K.S. Testosterone as a protective factor against atherosclerosis – immunomodulation and influence upon plaque development and stability // J. Endocrinol. – 2003. – Vol. 178, N 3. – P. 373-380.

McClung M.R., Geusens P., Miller P.D. et al. Effects of risedronate on the risk of hip fracture in elderly women // N. Engl. J. Med. – 2001. – Vol. 344. – P. 333-340.

McCormick R. Osteoporosis: Integrating biomarkers and other diagnostic correlates into the management ofbone fragility // Alternative Medicine Review. – 2007. – Vol. 12, N 2. – P. 113-145.

Mellstroom D.D., Sorensen O.H., Goemaere S. et al. A seven years of treatment with risendronate in women with postmenopausal osteoporosis // Calcif. Tissue Int. – 2004. – Vol.75, N 6. – P. 462-468.

Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermitten and continuous administration of the bisphosphonate ibandronate in ovarioectomized beagle dogs: effects on bone morphometry and mineral properties // J. Bone Miner. Res. – 1999. – Vol. 14. – P. 1768-1778.

Nguyen T.V., Center J.R., Eisman J.A. Osteoporosis: underdiagnosed and undertreated // Med. J. Aust. – 2004. – Vol. 180, N 5. – P. 18-22.

Nordin B.E.C., Need H.A., Morris H.A., Horowitz M., Robertson W.G. Evidence for renal calcium leak in postmenopausal women // J. Clin. Endocrinol. Metab. – 1991. – Vol. 72 – P. 401-407.

Notelovitz M. Androgen effects on bone and muscle. // Fertil. Steril. – 2002. – Vol. 77. Suppl. 4. – Р. 34-41.

Papapoulos S.E. Ibandronate: a potente new bisphosphonate in the management of postmenopausl osteoporosis // IJCP. – 2003. – Vol. 57. – P. 417- 422.

Prince R.L., Devin A., Dick I.M. The clinical utility of measured kyphosis as a predictor of presence of vertebral deformities // Osteoporos Int. – 2007. – Vol. 18, N 5. – Р. 621-627.

Prior J. Progesteron as bone trophic hormone // Endocr. Rev. – 1990. – Vol. 11(4). – P. 380-398.

Radioactive Heaven and Earth. The Health and Environmental Effects of Nuclear Weapons Testing In, On and Above the Earth: A Report of the IPPNW Internetional Comission To Investigate the Health and Environmental Effects of Nuclear Weapons Production and the Institute for Energy and Environmental Research / Ed. A. Robbins et al. – New York: The Apex Press, 1991. – 193 p.

Recker O.P., Delmas P.D., Halse J. et al. Effects of intravenous zoledronic acid once yerly on bone remodeling and bone structure // J. Bone Miner. Res. – 2008, Jan. – Vol. 23, N 1. – P. 6-16.

Recker R.R., Weinstein R.S. Chesnut C.H. et al. Histomorphmetric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the the BONE study // Osteoporosis Int. – 2004. – Vol. 15, N 3. – P. 231-237.

Rehman O., Lane N. Bone loss: Therapeutic approaches for preventing bone loss in inflammatory arthritis // Arthritis Res. – 2001. – Vol. 3, N 4. – P. 221-227.

Reid D.M. Methods of measurement of bone turnover and clinical evaluation of osteoporosis: relevance to asthma and corticosteroid therapy // Respir. Med. – 1993. – Vol. 87. – P. 9-14.

Rodan G., Reszka. A., Golub E., Rizzoli R. Bone safety of long-term bisphophonate treatment // Curr. Med. Res. Opin. – 2004. – Vol. 20, N 8. – P. 1291-1300.

Rogers M.J. New insights into molecular mechanisms of action ofbisphosphonates // Curr. Pham. Des. – 2003. – Vol. 9. – P. 2643-2658.

Roodman G.D. Advances in Bone Biology // The Osteoclast Endocr. Rev. – 1996. – Vol. 17 (4). – P. 308-332.

Roux C. Garneo P., Thomas T. et al. Comit Scientifique du GRIO. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis // Joint Bone Spine. – 2005 Jan. – Vol. 72, N 1. – P. 26-31.

Saag K., Lindsay R., Kriegman A. et al. A singl zoledronic acid infusion reduced bone resorption markers more rapildly then weekly oral alendronate in postmenopausal women with low bone mineral density // Bone. – 2007. – Vol. 40, N 5. – P. 1238-1243.

Shimizu Y., Kato H., Schull W.J. Studies of the mortality of A-bomb survivors. 9. Mortality, 19501985: Part 2. Cancer mortality based on the recently revised doses (DS86) // Radiat. Res. – 1990. – Vol. 121, N 2. – P. 120-141.

Siminoski K., Jiang G., Adachi J.D. et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures // Osteoporos Int. – 2005. – Vol. 16, N 4. – Р. 403-410.

Siminoski K., Warshawski R.S., Jen H., Lee K. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women // Osteoporos Int. – 2006. – Vol. 17, N 2. – Р. 290-296.

Stevenson J.C. Jastification for the use or HRH in the long-term prevention of osteoposis // Maturitas. – 2005. – Vol. 51, N 2. – P. 113-126.

Treatment or Osteoporosis. Workshop, Medical Products Agency, Uppsala, 1998. – P. 220.

University of Michigan Health System. Guidelines for Clinical Care: Osteoporosis: Prevention and Treatment, July 2005.

Van Staa T.P., Laan R.F., Barton I.P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy // Arthritis Rheum. – 2003. – Vol. 48, N 11. – P. 3224-3229.

Von Muhlen D.G. et al. Vitamin D, Parathyroid hormone levels and bone mineral density in community-dwelling older women: a Rancho Bernardo study // Оsteoporosis Int. – 2005. – N 16. – P. 1721-1726

Whitworth N.S., Meeks G.R. Hormone metabolism: Body weight and extraglandular estrogen production // Clin. Obstet. Gynec. – 1985. – Vol. 28 (3). – P. 580-587.

WHO Study Group «Assesment of fracture risk its application to screening for postmenopausal osteoporosis», Geneva, Switzerland: World Health Organization, 1994.